|
đ
|
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
15 auth.
D. Ross,
S. Branford,
J. Seymour,
A. Schwarer,
C. Arthur,
D. Yeung,
P. Dang,
J. Goyne,
C. Slader,
R. Filshie,
...
A. Mills,
J. Melo,
D. White,
A. Grigg,
T. Hughes
|
9 |
2013 |
9
đ
|
|
đ
|
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
9 auth.
D. White,
V. Saunders,
P. Dang,
J. Engler,
A. Zannettino,
A. Cambareri,
...
Steven R. Quinn,
P. Manley,
T. Hughes
|
8 |
2006 |
8
đ
|
|
đ
|
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
14 auth.
D. Ross,
S. Branford,
J. Seymour,
A. Schwarer,
C. Arthur,
P. Bartley,
C. Slader,
Chani R Field,
P. Dang,
R. Filshie,
...
A. Mills,
A. Grigg,
J. Melo,
T. Hughes
|
8 |
2010 |
8
đ
|
|
đ
|
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
12 auth.
D. Hiwase,
V. Saunders,
D. Hewett,
Amity Frede,
Stephanie Zrim,
P. Dang,
...
L. Eadie,
L. To,
J. Melo,
Sharad Kumar,
T. Hughes,
D. White
|
7 |
2008 |
7
đ
|
|
đ
|
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
9 auth.
D. White,
P. Dang,
J. Engler,
Amity Frede,
Stephanie Zrim,
M. Osborn,
...
V. Saunders,
P. Manley,
T. Hughes
|
7 |
2010 |
7
đ
|
|
đ
|
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
10 auth.
Debra L. White,
V. Saunders,
P. Dang,
J. Engler,
Amity Venables,
Stephanie Zrim,
...
A. Zannettino,
K. Lynch,
P. Manley,
T. Hughes
|
6 |
2007 |
6
đ
|
|
đ
|
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
17 auth.
Deborah L. White,
J. Radich,
S. Soverini,
V. Saunders,
Amity Frede,
P. Dang,
D. Cilloni,
Peter Lin,
Lidia Mongay,
Richard Woodman,
...
Paul Manley,
C. Slader,
Dong Wook Kim,
F. Pane,
Giovanni Martinelli,
G. Saglio,
T. Hughes
|
6 |
2012 |
6
đ
|
|
đ
|
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
18 auth.
D. Ross,
I. S. Pagani,
N. Shanmuganathan,
C. Kok,
J. Seymour,
A. Mills,
R. Filshie,
C. Arthur,
P. Dang,
V. Saunders,
...
Jodi A Braley,
A. Yong,
D. Yeung,
D. White,
A. Grigg,
A. Schwarer,
S. Branford,
T. Hughes
|
6 |
2018 |
6
đ
|
|
đ
|
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
9 auth.
L. Eadie,
P. Dang,
V. Saunders,
D. Yeung,
D. Yeung,
M. Osborn,
...
A. Grigg,
T. Hughes,
D. White
|
5 |
2017 |
5
đ
|
|
đ
|
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
27 auth.
S. Heatley,
Teresa Sadras,
C. Kok,
E. Nievergall,
Kelly Quek,
P. Dang,
B. McClure,
N. Venn,
S. Moore,
J. Suttle,
T. Law,
A. Ng,
Walter Muskovic,
M. Norris,
T. RĂŠvĂŠsz,
...
M. Osborn,
A. Moore,
R. Suppiah,
C. Fraser,
F. Alvaro,
T. Hughes,
C. Mullighan,
G. Marshall,
L. D. Pozza,
D. Yeung,
R. Sutton,
D. White
|
5 |
2017 |
5
đ
|
|
đ
|
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1
8 auth.
Deborah L. White,
Deborah L. White,
V. Saunders,
P. Dang,
Jane Engler,
Jane Engler,
...
Timothy P. Hughes,
Timothy P. Hughes
|
5 |
2010 |
5
đ
|
